We previously reported that susceptibility to childhood B cell precursor ALL (BCP ALL) is associated with HLA-DPB1 alleles having glutamic acid (E) rather than lysine (K) in the P4 antigenic peptide-binding pocket. Clustering B90% of DPB1 alleles into DPB69E (DP2, 6, 8) and DPB69K (DP1, 3, 4) supertypes revealed that DP2 and DP8 are associated with BCP ALL, but DP6 is also associated with non-BCP leukaemia. Here, we report that only one of seven alleles with the DP6 supertype (DPB1*0601) is associated with childhood leukaemia (leukaemia vs controls: odds ratio, 95% confidence interval [OR, CI]: 4.6, 2.0-10.4; corrected P ¼ 0.019), but not with childhood solid tumours or lymphomas. DPB1*0601 is also significantly associated with leukaemia subtypes, including BCP ALL, Pro-B ALL, T-ALL and AML. DPB1*0601 is significantly over-transmitted (76.9%) from parents to children with BCP ALL (OR; CI: 4.7; 1.01-22.2). Sequencing the coding region of DPB1*0601 revealed an exon 1-4 haplotype [T-DEAV-KIL-RVI] shared with DPB1*0301 and 0901, but no evidence of germline mutations in childhood leukaemia. These results suggest that the DPb0601 molecule may be functionally involved in childhood leukaemia. Analysis of peptide binding and T-cell activation by DPb0601-peptide complexes should help determine its role in childhood leukaemia causation.
Introduction
Childhood leukaemia is thought to arise by a two-step process initiated in utero by clonotypic chromosome rearrangement in a haemopoietic progenitor. [1] [2] [3] [4] Detection of covert leukaemic clones in the cord blood of term infants at an order of magnitude greater frequency than the incidence of childhood leukaemia 5 suggests that further molecular lesions, acquired during a variable post-natal latent period, are required to develop overt clinical disease. 3, 6 Epidemiological evidence indicates this promotional step may be mediated by a dysregulated immune response to delayed infection, but a causal agent has not as yet been identified. [7] [8] [9] [10] [11] Cancers strongly suspected of having an infectious aetiology but showing no evidence of a causative agent 12 may arise by a 'hit-and run' mechanism, in which the infectious agent initiates transformation, but is not thereafter required to maintain it. 13, 14 However, evidence in childhood leukaemia increasingly points to an active role for the immune response in the promotion of malignancy. 15 Alterations in the balance of cellular and humoral immunity, such as might occur during certain types of delayed neonatal infection, could be envisaged to lead to a pro-leukaemic immune environment. 16 However, difficulties in assessing the status of the immune response during the prodromal phase of leukaemia render this a particularly challenging problem. As HLA alleles are associated with and act as T-cell restricting elements for certain infections, 17, 18 HLA associations may serve as a proxy measure of infection and could be construed as supporting an infection-mediated pro-leukaemic immune aetiology.
HLA class II (DR, DQ, DP) molecules are coded by genes located in the human major histocompatibility complex on chromosome 6p21.3. 19 They consist of highly polymorphic heterodimeric receptors expressed by antigen-presenting cells, capable of binding peptides derived from infectious agents and tumours, resulting in the activation of antigen-specific CD4 þ helper T cells (Th) by peptide-HLA complexes. 20, 21 Polymorphisms in amino acids lining pockets in HLA class II molecules influence which amino acid side chain residues in antigenic peptides can be bound by an HLA class II molecule. In particular, the polymorphic residues lining peptide pockets 1, 4, 6 and 9 exert the strongest effect on peptide binding. 22 Previously, we reported that childhood B cell precursor ALL (BCP ALL) is associated with DPB1*0201 and other DPB1 alleles having a negatively charged glutamic acid (E) residue in the P4 pocket (DPB69E). 23 We suggested that this provided support for a dysregulated DP-restricted T-cell response to a DPb1*0201-peptide complex as a causal co-factor in BCP ALL. As different DPB1 alleles may share the same peptide pocket polymorphisms, we clustered alleles into supertypes, based on residues lining pockets 1, 4 and 6. About 90% of DPB1 alleles can be clustered into three supertypes with an E (B69E; DP2, 6, 8) , and three with a K (B69K; DP1, 3, 4) residue in the P4 pocket. 24, 25 These supertypes correspond to DP alleles defined by the primed lymphocyte typing test 26 and to DP supertypes identified by clustering algorithms. 27 We found that two of the three B69E supertypes (DP2, DP8) are significantly associated with BCP ALL, but the third, (DP6) is also associated with non-BCP leukaemia. 25 Here, we report on the results of further analysis of the DP6 supertype association with childhood leukaemia. We show that it is due exclusively to a single allele, DPB1*0601. We document, for the first time, the coding haplotype signature of the DPb0601 molecule, and consider its possible functional role in childhood leukaemia.
Materials and methods

Cases and controls
Blood samples from children with leukaemia (n ¼ 895) and solid tumours (excluding lymphoma; n ¼ 409) were obtained between 1992 and 1998, as part of the UK Childhood Cancer Study (UKCCS). 28 Samples from children with lymphoma (n ¼ 196) were also obtained in part during the UKCCS, and from North West of England. Blood samples were obtained from both parents (n ¼ 602) of 301 of the 687 children with BCP ALL as part of the UKCCS, 28 for the analysis of DP allele transmission in parent-child family trios. Genomic DNA was extracted from blood samples using standard methods. Case data (diagnoses, cytogenetics, ages, gender and ethnic background) were validated by the UKCCS data centre at the University of York. Diagnostic immunophenotyping of leukaemias was carried out on bone marrow as described earlier. 28 Leukaemias were classified as Pro-B ALL (CD10À, CD19 þ ); BCP ALL (CD10 þ , CD19 þ ); T-ALL (CD2/CD7 þ , CD19À, DRÀ) and AML. Solid tumour cases and lymphomas were identified by histopathological review by tumour-specific pathology review panels, as described earlier. 28 Unrelated controls comprised a crosssectional series of normal term newborns delivered at St Mary's Hospital, Manchester, UK (n ¼ 864), between 1991 and 1997. The male/female ratio of the total case series was 1.23:1; for the controls it was 1.01:1. Buccal samples from age-matched UKCCS control children (n ¼ 99) were obtained in the North West of England. All procedures were carried out with national and local ethical approval.
Conventional and molecular cytogenetics of leukaemias
Cytogenetic analysis of leukaemia cases was carried out as described earlier 24 on diagnostic bone marrow and/or peripheral blood samples by local UK cytogenetic laboratories according to standard methods, and reviewed by the Leukaemia Research Cytogenetics Group (Newcastle, UK). 24, 28, 29 Bone marrow and peripheral blood of cases with cells carrying TEL-AML1 transcripts were detected using RT-PCR and fluorescence in situ hybridization. Cases with a high hyperdiploid (HeH) leukaemia karyotype were identified either by conventional cytogenetic analysis or, in cases of a failed cytogenetic result, by interphase fluorescence in situ hybridization as described earlier. 24 
Lymphoblastoid cell lines
Lymphoblastoid cell lines (LCL) were prepared by immortalizing frozen stored remission lymphocytes from selected childhood leukaemia cases using the B95-8 strain of Epstein-Barr virus. 30 The normal Caucasoid human lymphoid cell line CAD, KR (HLA-A2;B7,41;DRB1*0405,*1501;DPB1*0401,*0601) was obtained from the European Collection of Cell Cultures (ECACC, Porton Down, UK). LCL were grown in suspension culture in RPMI-1640, containing 10% fetal calf serum and antibiotics.
HLA-DPB1 molecular typing HLA-DPB1 molecular typing was carried out as previously described. 23 A 327 bp fragment of DPB1 exon 2 was amplified from genomic DNA using a pair of DPB1 generic PCR primers. Aliquots of each PCR product were hybridized with a panel of 28 32 P-labelled sequence-specific oligonucleotide probes, and hybridization detected using real-time autoradiography. DPB1 alleles were assigned from published sequence-specific oligonucleotide probe ideograms.
HLA-DPB1 sequence-based typing HLA-DPB1 sequence-based typing (SBT) 31 was carried out by direct sequencing of DPB1 exon 2 using AlleleSEQR HLA-DPB1 SBT kits (Abbott Laboratories, Berkshire, UK), according to the manufacturer's instructions (http://international.abbottmolecular. com/PDF/AlleleSEQR_CE_HLAflyerEmail.pdf). PCR amplification was carried out in PCR buffer/Taq enzyme (8 ml) and genomic DNA (2 ml of 20ng/ml) for 10 min (95 1C), followed by 36 cycles (20 s/96 1C; 30 s/60 1C; 3 min/72 1C) and quality checked on 1% agarose gels stained with ethidium bromide. Samples were denatured (2 min/95 1C) and sequenced on an ABI 3130 Genetic Analyser (Applied Biosystems, Warrington, UK). DPB1 alleles were identified using Assign-SBT version 3.2.7 32 (Conexio Genomics, Freemantle, Australia).
Complete sequencing of the HLA-DPB1-coding region
The complete DPB1-coding region was sequenced using cDNA derived from LCL by the method of Reinders et al. 33 with modifications. Total RNA was extracted from LCL (8 Â 10 6 ) and cDNA synthesized using TRIzol and Superscript II (Invitrogen, Paisley, UK), respectively, according to the manufacturer's protocols. cDNA was amplified using the 5 0 UTR primer DPRNARG5.1 (TCCCTTTAGCGAGTCCTTC) and 3 0 UTR primer DPRNARG3 (CTTCTT GGCAGCAGTATCC) sequences kindly provided by Dr MG Tilanus (University of Utrecht, Netherlands), as described by Reinders et al. 33 Reactions ( Data analysis DPB1 allele frequencies were compared using univariate statistical analysis to calculate cross-product odds ratios (ORs) and 95% confidence intervals (CI) by the Sheehe method, with the RERI program from the Linkage Utility Package (LINKUTIL: http://linkage.rockefeller.edu/soft/linkutil/) as described earlier. 23 Statistical significance of case-control allele frequency comparisons was determined using Fisher's Exact test to calculate P-values using the 2by2 programme in LINKUTIL. Results are depicted as 2-sided P-values, with corrections for the number of DPB1 alleles and DP supertypes applied as described. The transmission disequilibrium test (TDT) was carried out using a conditional logistic regression model in HLA phase-certain informative BCP ALL family trios (that is, father, mother and affected child) with complete DP types, using the TDTPHASE program in the UNPHASED (version 3.0.13) suite of programs (UNPHASED; http://www.mrc-bsu.cam.ac.uk/ personal/frank/software/unphased/). This calculates odds ratios (OR) for deviations of transmitted DPB1 allele frequencies from 50% Mendelian expectation using DPB1*0401 as reference allele. 34 Logistic regression analysis of DPB1 alleles was carried out using Stata 8 (StataCorp LP, Lakeway Drive, College Station, TX, USA).
Results
Frequency of DP6 supertype alleles
To determine which of the seven alleles carrying the DP6 supertype (DPB1*0601, 0901, 1001, 1301, 1701, 2101, 3001) present in the DP-typed UKCCS population-based series of childhood leukaemias (n ¼ 895) and childhood solid tumours (CST; n ¼ 409; excluding lymphomas) is associated with these diseases, allele frequencies were compared with newborn controls (n ¼ 864). Table 1 shows that only one allele with the DP6 supertype (DPB1*0601) is significantly associated with childhood leukaemia (OR, CI: 4.6, 2.0-10.4; uncorrected 2-sided P ¼ 10 À5 correction for 33 DPB1 alleles and six DP supertypes, P ¼ 0.019), but not with CST (OR, CI: 0.8, 0.2-3.1; uncorrected P ¼ 0.9). DPB1*0901 is significant in CST, but not after correction for alleles and supertypes. Analysis of data stratified by leukaemia subtype (Table 2) shows that 0601 is significantly more frequent in ALL (OR, CI: 4.5, 1.9-10.4; correction for 33 DPB1 alleles and six DP supertypes: P ¼ 0.039), and, without correction, in AML (OR, CI: 5.7, 1.8-18.0; P ¼ 0.035) than in controls. DPB1*0601 is also significantly more frequent (after correction for six supertypes, but not for 33 alleles) in BCP ALL (OR, CI: 3.6, 1.5-8.6; P ¼ 0.026), Pro-B ALL (OR, CI: 18.7, 5.3-66.1; P ¼ 0.02) and T-ALL (OR, CI: 10.0, 3.3-30.2; P ¼ 0.011). DPB1*0601 is completely absent from childhood Hodgkin's lymphoma (n ¼ 85), and not significant in nonHodgkin's lymphoma (n ¼ 111), or in UKCCS age-matched normal controls (n ¼ 99), compared with newborn controls.
Logistic regression analysis using DPB1*0401 [DP4] as the reference allele (Figure 1) (Table 3) into those with TEL-AML1 transcripts, those with an HeH karyotype or 'Other' (that is, non-TEL-AML1, non-HeH) karyotypes reveals significantly increased frequencies of DPB1*0601 in TEL-AML1 and HeH, but a stronger association with 'Other' cases. This may be because of a lower proportion of BCP ALL (44%) in leukaemias with 'Other' karyotypes (and a higher percentage of non-BCP leukaemias) compared with those having TEL-AML1 (94%) transcripts or an HeH karyotype (91%). 
TDT analysis in BCP ALL family trios
Linkage analysis using the transmission disequilibrium test, carried out in informative BCP ALL family trios (n ¼ 301), consisting of both parents and affected child, shows a DPB1*0601 transmission rate of 76.9%. The case-control (that is, transmitted vs non-transmitted) odds ratio (95% confidence interval) for 0601, using 0401 as reference allele, is 4.7 (1.01-22.2). Testing 0601 for transmission disequilibrium vs all other DP alleles combined gives a significant w 2 (4.45; P ¼ 0.034). Evidence that fathers transmit 0601 at a higher frequency (86%) than mothers (67%) is suggestive of a parent-of-origin effect, but bigger numbers are required for confirmation. Partial HLA class II (DPB1-DQA1-DQB1) haplotypes obtained by pedigree analysis of 301 informative BCP ALL family trios were identified in children with 0601 in seven families, including three with 0601-0103-0603, two with 0601-0101-0501, one with 0601-05-0201 and one with 0601-0201-0201.
DPB1 sequence-based typing and coding sequence analysis
As DPB1*0601 shows only limited sequence differences with other DPB1 alleles such as 2001, 0301 and 0901, we verified the assignment of 0601 in putative 0601 þ leukaemia cases (n ¼ 18) and newborn controls (n ¼ 5) using SBT. Here, of the 23 samples, 0601 was verified in 18; two case samples being 2001, one 1701, one 1001 and one 0201. None of the controls were mistyped. These results are incorporated into the 0601 frequency analysis in Tables 1-3. As some of the mistyped cases might have been mutants, we sequenced the entire DPB1*0601 coding region in three patients, and compared it with a DPB1*0601 þ control LCL (CAD, KR). All four samples have identical exon 2 sequences consistent with DPB1*0601, with no evidence of mutations. The complete coding sequence of DPB1*0601 (Figure 2 ) reveals an exon 1-4 haplotype (T-DEAV-KIL-RVI) identical to the DP3 (B69K ) allele, 0301 and the DP6 (B69E ) allele, 0901, but different from DPB1*0602 and 0902 (Table 4) .
Discussion
We reported earlier that childhood BCP ALL is associated with HLA-DPB1 alleles having a glutamic acid (E) residue in the P4 peptide-binding pocket (DPB69E ). 23 Clustering of DPB1 alleles into six supertypes with either E or K in the P4 pocket enabled us to distinguish three DPB69E (DP2, DP6, DP8) from three DPB69K (DP1,DP3, DP4) supertypes. 24, 25 Two of the B69E supertypes (DP2, DP8) are associated with BCP ALL, but the third (DP6) is more strongly associated with non-BCP leukaemia than with BCP ALL. 25 In this study, we investigated the unexpected association between DP6 and leukaemia in further detail.
DP2, 6 and 8 are all DPB69E supertypes, but DP6 alone has leucine [L] in the P6 pocket.
25 DP6 and DP8 both have aspartic acid [D] in the P1 pocket, and DP2 and DP8 have glycine [G] in the P6 pocket. Thus, although a negatively charged E, rather than a positively charged K in pocket 4 of DPB1 35 is an important mediator of susceptibility in childhood leukaemia, 25 L in pocket 6 appeared to encompass associations with all leukaemia subtypes. However, we show that of seven alleles with the DP6 supertype, only one (DPB1*0601) is associated with leukaemia. Though uncommon, 0601 is four times more frequent in children with leukaemia than in controls. In contrast, DPB1*0901, a DP6 allele which differs from 0601 by only three residues at b76) appears to be negatively associated with childhood leukaemia (Table 1) . Furthermore, DPB1*1701 a DP6 allele, which differs from 0601 by two residues (Y instead of H at b9; L for I at b65) is only weakly associated with leukaemia. Our results thus suggest that among DP6 alleles, an E in the P4 pocket (position 69) and methionine (M) in the P4/6 pocket (position 76) may be key residues influencing the association of 0601 with childhood leukaemia. As b76M contributes to the negative charges in pocket 4, and pocket 6, 35 one possibility is that it might influence the binding of the P4 and P6 residues of a peptide associated with childhood leukaemia.
Our results raise the question whether DPB1*0601 plays a direct or indirect role in the causation of childhood leukaemia.
It seems unlikely that the DPb0601 molecule participates in a 'hit-and-run' 13,14 type infection, because all 0601 þ cases are It is possible that 0601 binds an infection-derived peptide that elicits a dysregulated inflammatory response 16 capable of promoting leukaemia in children already carrying a pre-leukaemic clone. However, UKCCS case children with BCP ALL (n ¼ 336) typing for DPB1*0601 failed to show a higher frequency of infection in the first year of life (infection vs no infection: 6.2 vs 9.4%; J Simpson, UKCCS personal communication).
Nonetheless, this does not discount an 0601-restricted response to subclinical infection. Further analysis of DP supertype, childhood leukaemia and infection will be presented elsewhere.
Evidence from other studies points to a role for the targeting of 0601 by bioactive molecules. Beryllium (Be) binds to DPb69E molecules resulting in Be hypersensitivity and chronic beryllium disease, an autoimmune granulomatous lung condition. 36, 37 DPB1*0601 is also associated with the development of auto-antibodies to caspase 8 in patients with silicosis, 38 and topoisomerase I antibody in patients with idiopathic and uranium-induced systemic sclerosis. 39 There are no reports of associations between childhood leukaemia and these diseases, but these interactions between DPb0601 and specific environmental agents warrant further investigation in childhood leukaemia.
Our results show that childhood leukaemia, but not childhood solid tumours or lymphomas are associated DPB1*0601, suggesting that the expression of 0601 by bone marrow may be an important co-factor in the promotion of leukaemia. As DP molecules are selectively expressed by bone marrow progenitors, a BM-presented 0601-peptide complex may be capable of eliciting or sustaining a localized inflammatory pro-leukaemic reaction.
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We found no evidence of mutations in the DPB1*0601-coding sequence in leukaemia that might perturb peptide binding. Furthermore, the exon 1-4 coding haplotype of 0601, T-DEAV-KIL-RVI is also found in DPB1*0301 and 0901, evidence suggesting a common evolutionary origin of the three alleles. Reinders et al. 33 proposed that DEAV-KI-RVI is one of the two ancient DPB1 lineages that includes DPB1*0901, 0902, 1301 and 1401. Interestingly 0301, which differs from 0601 only by E in the P4 pocket, also has D in the P1 and L in the P6 pockets, but is not associated with childhood leukaemia. 23, 25 Acquisition of E (P4 pocket) and M (P4 and P6 pockets) by 0601, perhaps by recombination of the D and E hypervariable regions of 0301 with some other allele could have resulted in a combination of residues that increased the risk of leukaemia.
Childhood leukaemia is a disease with a complex aetiology, likely consisting of parental and fetal genetic contributions. 41 Over-transmission of 0601 from parents to children with BCP ALL, detected by the TDT analysis, indicates a fetal, rather than maternal contribution of this allele to susceptibility. Evidence of four different DPB1-DQA1-DQB1 haplotypes in the children of seven sets of parents carrying DPB1*0601 suggest that 0601 is not a marker of an extended ancestral leukaemia-linked major histocompatibility complex haplotype encompassing the DP and DQ loci. Furthermore, among immediate DP-flanking genes, neither the bromodomain-containing protein 2 (BRD2; (OMIM 42 ) MIM 601540), collagen type X1 (COL11A2; MIM 120290), ring finger protein 1 (RING1; MIM 602045) nor the 17-b-hydroxysteroid dehyrogenase VIII (HSD17B8; MIM 601417) genes seem to be plausible candidates for an 0601-linked 'leukaemia gene'. However, the retinoid X receptor b (RXRB; MIM 180246) gene 43 may warrant further study. RXRB is a heterodimerization partner for a family of nuclear hormone receptors activated by 9-cis-retinoic acid, a metabolite of vitamin A. Three variants are in LD with DPB1*0101, 0201, 0301, 0401 and 0402, 44, 45 but LD with 0601 has not been reported. RXRB antagonists inhibit Th2-mediated immunity, blocking the development of allergy, 46 and vitamin A enhances Th2 development through the RXR pathway. 47 In view of the inverse relationship between allergy, a Th2-mediated condition and childhood leukaemia [48] [49] [50] a more detailed examination of RXRB isotypes may be justified.
To conclude, we report that DPB1*0601 is strongly associated with a minority of childhood leukaemias. This association may indicate an interaction between a bioactive molecule, perhaps derived from an infection and the DPb1*0601 protein, localized in the fetal or neonatal bone marrow, leading to a proleukaemic inflammatory reaction.
